Clinical Trials

Study Title:
An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-355 and BBI-355 in Combination with Select Targeted Therapies in Subjects with Locally Advanced or Metastatic Solid Tumors with Oncogene Amplifications

For more information about the trial above please contact the study team:

Medical University of South Carolina
Principal Investigator, Thai Ho, at hothai@musc.edu.
Study Coordinator, Holly Boggan, at bogganhl@musc.edu, or please call +1 843-792-8068.

Trial opened at the following institutions: Medical University of South Carolina